The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BNR | +196.37% | -91.94% | -39.55% | -92% |
| S&P | +12.66% | +85.37% | +13.13% | +125% |
Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The firm operates through the following segments: Central Laboratory Business, In-Hospital Business and Pharma Research and Development Services. Its products and clinical applications include companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction and tumor susceptibility tests. The company was founded by Yu Sheng Han in January 2014 and is headquartered in Guangzhou, China.
No news articles found for Burning Rock Biotech.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $18.39M | 2.5% |
| Gross Profit | $13.81M | 7.8% |
| Gross Margin | 75.10% | 3.7% |
| Market Cap | $78.16M | 181.2% |
| Market Cap / Employee | $0.12M | 0.0% |
| Employees | 674 | -14.2% |
| Net Income | -$2.34M | 53.1% |
| EBITDA | -$1.96M | 57.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $65.60M | -7.6% |
| Accounts Receivable | $27.66M | 2.4% |
| Inventory | 7.7 | -19.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.30M | -77.9% |
| Short Term Debt | $2.36M | -40.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.24% | 26.2% |
| Return On Invested Capital | -57.11% | -6.4% |
| Current | YOY Change | |
|---|---|---|
| Operating Free Cash Flow | $2.21M | 153.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.60 | 0.40 | 0.43 | 1.18 | 297.08% |
| Price to Sales | 0.97 | 0.67 | 0.46 | 1.25 | 162.25% |
| Price to Tangible Book Value | 0.60 | 0.40 | 0.36 | 0.99 | 233.07% |
| Enterprise Value to EBITDA | -2.73 | 8.75 | 19.04 | -16.45 | -426.91% |
| Return on Equity | -51.2% | -37.1% | -22.7% | -19.9% | -64.71% |
| Total Debt | $7.17M | $5.84M | $5.46M | $4.66M | -67.59% |
No podcast episodes available.
BNR earnings call for the period ending June 30, 2022.
BNR earnings call for the period ending March 31, 2022.
BNR earnings call for the period ending December 31, 2021.
BNR earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
